278 related articles for article (PubMed ID: 28919099)
1. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
[TBL] [Abstract][Full Text] [Related]
2. Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate.
Basa-Dénes O; Solymosi T; Ötvös Z; Angi R; Ujhelyi A; Jordán T; Heltovics G; Glavinas H
Eur J Pharm Sci; 2019 Mar; 129():79-86. PubMed ID: 30610953
[TBL] [Abstract][Full Text] [Related]
3. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
5. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.
Schultz HB; Meola TR; Thomas N; Prestidge CA
Int J Pharm; 2020 Mar; 577():119069. PubMed ID: 31981706
[TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
7. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
Geboers S; Stappaerts J; Mols R; Snoeys J; Tack J; Annaert P; Augustijns P
J Pharm Sci; 2016 Sep; 105(9):2974-2981. PubMed ID: 27061460
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
[TBL] [Abstract][Full Text] [Related]
11. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
12. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
13. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.
Cundy KC; Sue IL; Visor GC; Marshburn J; Nakamura C; Lee WA; Shaw JP
J Pharm Sci; 1997 Dec; 86(12):1334-8. PubMed ID: 9423141
[TBL] [Abstract][Full Text] [Related]
14. Novel continuous flow technology for the development of a nanostructured aprepitant formulation with improved pharmacokinetic properties.
Angi R; Solymosi T; Ötvös Z; Ordasi B; Glavinas H; Filipcsei G; Heltovics G; Darvas F
Eur J Pharm Biopharm; 2014 Apr; 86(3):361-8. PubMed ID: 24161498
[TBL] [Abstract][Full Text] [Related]
15. Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent.
Aungst BJ; Nguyen NH; Taylor NJ; Bindra DS
J Pharm Sci; 2002 Jun; 91(6):1390-5. PubMed ID: 12115838
[TBL] [Abstract][Full Text] [Related]
16. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
[TBL] [Abstract][Full Text] [Related]
17. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
18. Selection of oral bioavailability enhancing formulations during drug discovery.
Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
[TBL] [Abstract][Full Text] [Related]
19. Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling.
Dahiya S; Savjani K; Savjani J
AAPS PharmSciTech; 2021 Nov; 23(1):4. PubMed ID: 34811624
[TBL] [Abstract][Full Text] [Related]
20. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
Schultz HB; Joyce P; Thomas N; Prestidge CA
Pharm Res; 2020 Mar; 37(4):77. PubMed ID: 32236761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
